Alixir is working on the mammographic detection system of the future, combining instant reporting with accuracy that exceeds a radiologist. Early studies of Alixir's breast cancer screening system have shown a sensitivity of over 95% and a specificity of 93% on a well-established segmented test set for digital mammography. Alixir's technology can interpret and report on an entire mammography study in a mere 1.4 seconds, expediting necessary callbacks and saving lives. Alixir can augment or replace a human read, making the screening process more accurate and more cost effective than ever before.
matchstiq.ioPart of: NZ & Aus Startups Map